We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.07%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
26
Xencor
XNCR
$2.07B
$21.4M 0.19%
872,072
– –
HALO icon
27
Halozyme
HALO
$12.3B
$20.9M 0.19%
1,731,057
-107,000
-6% -$1.09M
ACHN
28
DELISTED
Achillion Pharmaceuticals
ACHN
$20.1M 0.18%
2,475,515
– –
BLUE
29
DELISTED
bluebird bio
BLUE
$19.9M 0.18%
22,692
– –
MRUS
30
DELISTED
Merus
MRUS
$19.4M 0.18%
1,160,014
+37,155
+3% +$353K
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$18.8M 0.17%
4,055,876
– –
NTLA icon
32
Intellia Therapeutics
NTLA
$1.8B
$18.1M 0.16%
1,062,120
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$18M 0.16%
51,625
+96
+0.2% +$25.4K
DSCI
34
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$17.5M 0.16%
3,752,390
– –
LKFT
35
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$16.8M 0.15%
259,894
– –
TGTX icon
36
TG Therapeutics
TGTX
$8.31B
$15.5M 0.14%
2,003,991
– –
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15M 0.14%
2,269,198
– –
ASND icon
38
Ascendis Pharma A/S
ASND
$16.6B
$15M 0.14%
745,521
– –
ARWR icon
39
Arrowhead Research
ARWR
$12.3B
$13.6M 0.12%
1,856,967
+847,458
+84% +$5.49M
VTAE
40
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$13.3M 0.12%
637,597
– –
ALKS icon
41
Alkermes
ALKS
$8.11B
$11.8M 0.11%
250,251
– –
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$11.4M 0.1%
1,000,000
– –
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$11.3M 0.1%
299,356
– –
DERM
44
DELISTED
Dermira, Inc.
DERM
$11M 0.1%
326,428
– –
AGIO icon
45
Agios Pharmaceuticals
AGIO
$1.98B
$11M 0.1%
207,915
– –
MGNX icon
46
MacroGenics
MGNX
$261M
$10.9M 0.1%
363,676
– –
AIMT
47
DELISTED
Aimmune Therapeutics
AIMT
$10.1M 0.09%
673,908
– –
CFRX
48
DELISTED
ContraFect Corporation
CFRX
$10M 0.09%
+5,057
New +$9.93M
DMTX
49
DELISTED
Dimension Therapeutics, Inc
DMTX
$10M 0.09%
1,251,881
– –
SAGE
50
DELISTED
Sage Therapeutics
SAGE
$9.59M 0.09%
208,328
-15,720
-7% -$640K
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2016 Portfolio in Review

As of Q3 2016, Julian Baker held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in ContraFect Corporation worth $10M.

  • Julian Baker's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Julian Baker added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Julian Baker's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Julian Baker fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Julian Baker's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Julian Baker opened 7 new positions and closed 6 in Q3 2016.
  • Julian Baker's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.